Myth or truth: The glass forming ability class III drugs will always form single-phase homogenous amorphous solid dispersion formulations

18Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

Abstract

The physical stability of amorphous solid dispersions (ASD) of active pharmaceutical ingredients (APIs) of high glass forming ability (GFA class III) is generally expected to be high among the scientific community. In this study, the ASD of ten-selected class III APIs with the two polymers, PVPVA 64 and HPMC-E5, have been prepared by spray-drying, film-casting, and their amorphicity at T0 was investigated by modulated differential scanning calorimetry and powder X-ray diffraction. It was witnessed that only five out of ten APIs form good quality amorphous solid dispersions with no phase separation and zero crystalline content, immediately after the preparation and drying process. Hence, it was further established that the classification of an API as GFA class III does not guarantee the formulation of single phase amorphous solid dispersions.

Cite

CITATION STYLE

APA

Panini, P., Rampazzo, M., Singh, A., Vanhoutte, F., & Van den Mooter, G. (2019). Myth or truth: The glass forming ability class III drugs will always form single-phase homogenous amorphous solid dispersion formulations. Pharmaceutics, 11(10). https://doi.org/10.3390/pharmaceutics11100529

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free